Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (CORRECT-MRD II)
Study Number: NSABP C-14
Study Summary:
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Status: Open
Bloomington, Canton, Galesburg, Ottawa, Pekin, Peoria, Peru, and Washington clinics
Study Coordinator(s)
- Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
- Beth, 309-243-3617 bheilman@illinoiscancercare.com
